Navigation Links
ULURU Inc. Reports Second Quarter 2013 Financial Results
Date:8/15/2013

ting plan and a lower head count, a decrease of $88,000 in investor relations consulting and a decrease of $42,000 in insurance costs.

Other income and Other expenses

Interest expense for the second quarter of 2013 was $128,000 as compared to $31,000 for the second quarter of 2012.  The increase of approximately $97,000 is primarily attributable to costs associated with our convertible debt.

About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the advancement of licensing discussions for additional markets, the anticipated launch of Altrazeal® in various markets and countries, the demonstration of clinical benefits and cost benefits of Altrazeal®,  the completion of strategic alliances, the anticipated escalation of revenues, positive cash flows, and improved profitability in 2013, and the acceptance of Altrazeal® by medical practitioners.  When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements including without limitation statements re
'/>"/>

SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
2. ULURU Inc. Reports First Quarter 2013 Financial Results
3. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
4. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
6. ULURU Inc. Business Update And Outlook
7. ULURU Inc. Announces Closing Of $440,000 Private Placement
8. ULURU Inc. Reports Third Quarter 2012 Financial Results
9. ULURU Inc. Announces The First Shipment Of Veterinary Product
10. ULURU Inc. Announces First Order Of Altrazeal For European Launch
11. ULURU Inc. Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) ... year 2014 financial results on Tuesday, Jan. 27, 2015, after the ... by a conference call with the investment community at 2 p.m. ... A. Bradway , chairman and chief executive officer, and other members ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Infectious Disease Diagnostics Market by Product, Application, Technology, ... to their offering. , The infectious disease ... 7.9% to reach $18,156.2 million by 2019 from $12,422.8 ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... 5 ResMed Inc. (NYSE: RMD ), a ... medical equipment, announced today that it has acquired Laboratoires ... the Narval O.R.M.(TM), an innovative mandibular repositioning device (MRD) ... obstructive sleep apnea (OSA), especially for those with mild ...
... following letter is being released by CEL-SCI Corporation (NYSE ... Shareholders: , After FDA had communicated several weeks ago that ... proposed H1N1 treatment for hospitalized H1N1 patients, we have received ... mind, we have asked one of our outside collaborators, Ken ...
Cached Medicine Technology:ResMed Acquires Laboratoires Narval 2ResMed Acquires Laboratoires Narval 3CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 5CEL-SCI Corporation Releases Letter to Shareholders 6CEL-SCI Corporation Releases Letter to Shareholders 7
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... guard personal health information against nature,s devastation , , ... chaos, destruction and death. Now is the time of year ... the high-impact storm systems that will sweep across many parts ... for the possibility of a dangerous tropical storm striking near ...
... ... ... -- Today, the National Association of Chain Drug Stores (NACDS), the National ... briefing on the benefits of pharmacist-provided medication therapy management (MTM). NACDS, Senior Vice ...
... New "Big Pharma" Section Added to Green America,s Web Site ... Pfizer and Sanofi Aventis Bring Up Rear. , ... corporations in your medicine cabinet good companies or bad companies? ... added "Big Pharma" section of Green America,s consumer watchdog Web ...
... aid suicide prevention, researchers suggest , TUESDAY, June 9 ... nightmares might be linked to an increased risk of ... men and women, ages 18 to 66, who were ... a community mental health hospital. They were asked about ...
... thoughts as well, study finds , TUESDAY, June 9 (HealthDay ... at 10 p.m. are less apt to become depressed or ... later, recent research shows. , "This study bolsters the argument ... author James Gangwisch, an assistant professor of psychiatry at Columbia ...
... Life Beyond Cancer (LBC), an advocacy program ... applications from cancer survivors, oncology nurses, social workers, oncologists, primary care physicians, ... Miraval luxury resort in Catalina, Ariz., is offered ... Eisai , Gold Sponsors Abraxis Oncology ...
Cached Medicine News:Health News:PHRs Protect Families From the Harshest Realities of Natural Disasters 2Health News:PHRs Protect Families From the Harshest Realities of Natural Disasters 3Health News:Pharmacy Organizations Brief Congress on Medication Therapy Management 2Health News:Pharmacy Organizations Brief Congress on Medication Therapy Management 3Health News:ResponsibleShopper.org: What Do You Know About The Companies In Your Medicine Cabinet? 2Health News:ResponsibleShopper.org: What Do You Know About The Companies In Your Medicine Cabinet? 3Health News:ResponsibleShopper.org: What Do You Know About The Companies In Your Medicine Cabinet? 4Health News:Early Bedtime May Help Stave Off Teen Depression 2Health News:Early Bedtime May Help Stave Off Teen Depression 3Health News:Life Beyond Cancer Women's Retreat Calls for Applications 2Health News:Life Beyond Cancer Women's Retreat Calls for Applications 3
... AngioSpeed VH series, it is ... 2 independent C-arms and image ... dedicated for Cardiovascular and Angiography. ... perform the examinations for cerebral, ...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Rubidium Rb 82 Generator. ,The only generator-based Positron Emission Tomography agent reimbursed for the evaluation of coronary artery disease....
Kit for the Preparation of Technetium Tc 99m Teboroxime...
Medicine Products: